Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Kexiong Qiao

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5008967080. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

  1. Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently. Co-author DOI 10.1038/s41698-026-01396-z↗
  2. Discovery of an 8-oxoguanine regulator PCBP1 inhibitor by virtual screening and its synergistic effects with ROS-modulating agents in pancreatic cancer. Co-author DOI 10.3389/fmolb.2024.1441550↗
  3. VRK2 activates TNFα/NF-κB signaling by phosphorylating IKKβ in pancreatic cancer. First author DOI 10.7150/ijbs.66313↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chaolei Zhang · 3 shared papers, 2022–2026 · strength 0.69
  2. Shengnan Jia · 2 shared papers, 2024–2026 · strength 0.52
  3. Liangjing Zhou · 2 shared papers, 2024–2026 · strength 0.52
  4. Liping Cao · 2 shared papers, 2022–2024 · strength 0.39
  5. Xiaofan Pu · 1 shared paper, 2026 · strength 0.30
  6. Jionghuang Chen · 1 shared paper, 2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.